Sensibility of Entamoeba histolytica trophozoites to ivermectin

Centro de Investigaciones Biomédicas del Noreste, Instituto Mexicano del Seguro Social, Mexico.
Medicina (Impact Factor: 0.56). 02/2009; 69(3):318-20.
Source: PubMed


Amebiasis caused by Entamoeba histolytica is a problem of public world health. The most frequent clinical presentation are the dysentery and the amebic liver abscess. Fifty millions of cases and more than 100.000 deaths for this disease are reported annually worldwide. The life cycle of E. histolytica has two phases: trophozoite and cyst. Trophozoites are the causal agent of disease. The effective treatment for the amebiasis includes drugs with serious collateral effects. Ivermectin is a macrolid with activity against endoparasites and ectoparasites causing strongiloidosis, filariasis, oncocercosis, scabiasis and pediculosis. The use of ivermectin has been extended almost worldwide; it is recognized as a safe drug. The main objective of this study was to determine in vitro sensibility of trophozoites of E. histolytica was to the treatment with ivermectin. To determine the sensibility of the parasites to the drug, E. histolytica was cultivated in PEHPS medium. During its logarithmic growth phase the trophozoites were exposed to different concentrations of ivermectin. As controls other antiparasitic drugs were used. For each drug, serial dilutions were prepared, and mixed in culture tubes with parasites (2 x 104 cells/ml). They were incubated for 72 h and then the percentage of growth inhibition was calculated by Probit analysis. Ivermectin showed activity against trophozoites of E. histolytica. The 50% of growth inhibition of ivermectin was 6.40 mg/ml. This dose was higher than for other anti parasitic drugs. Its activity in vivo in animal models remains to be demonstrated.

Download full-text


Available from: Francisco Gonzalez-Salazar
  • Source
    • "Recently some studies have also indicated a potential use of ivermectin for amebiasis (González-Salazar, et al 2009). "

    Full-text · Chapter · Jan 2012
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many lung infestations from established and newly emerging parasites have been reported as a result of the emergence of HIV/AIDS, the increasing use of immunosuppressive drugs, increasing organ transplantations, the increase in global travel, and climate change. A renewed interest in parasitic lung infections has been observed recently because many protozoal and helminthic parasites cause clinically significant lung diseases. The diseases caused by these parasites may mimic common and complicated lung diseases ranging from asymptomatic disease to acute respiratory distress syndrome requiring critical care management. The availability of new molecular diagnostic methods and antiparasitic drugs enables early diagnosis and prompt treatment to avoid the morbidity and mortality associated with these infestations. Good hygiene practices, improvement in socioeconomic conditions, vector control measures, and consumption of hygienically prepared and properly cooked food are essential to reduce the occurrence of parasitic infestations.
    No preview · Article · Sep 2010 · Infectious disease clinics of North America
  • [Show abstract] [Hide abstract]
    ABSTRACT: Trichomoniasis is the most common, curable sexually transmitted disease in the world. The first line treatment of trichomoniasis is metronidazole. Recently, the resistance of T. vaginalis to metronidazole and imidazoles has been shown to increase. Ivermectin is a synthetic machrolid drug with activity versus endo and ectoparasitic organisms. In this assay, was tested the effects of ivermectin on T. vaginalis trophozoites. Ivermectin have anti-parasitic activity upon trichomonas trophozoites. However, the IC 50 of ivermectin against T. vaginalis was high compared with metronidazole.
    No preview · Article · Feb 2012 · LATIN AMERICAN JOURNAL OF PHARMACY
Show more